Trial Profile
Phase III Randomised Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Lymphoproliferative disorders
- Focus Therapeutic Use
- Acronyms IDRIS
- 17 May 2021 Planned primary completion date changed from 1 Oct 2022 to 1 Apr 2026.
- 17 May 2021 Status changed from recruiting to active, no longer recruiting.
- 22 Oct 2019 Planned End Date changed from 1 Dec 2025 to 1 Dec 2026.